2 NK 2 double negative T cells (DN T cells) can act as regulatory T cells to inhibit allograft rejection and autoimmunity. Their role in graft-versus-host disease and mechanisms of suppression remain elusive. In this study, we demonstrate that DN T cells can inhibit CD4
Introduction
DN T cells express an ab T cell receptor (TCR) but do not express either CD4 or CD8 coreceptors, nor do they express NK cell markers. This phenotype differentiates them from other unconventional T cells (e.g. NK T cells and cd T cells). Depending on the context, DN T cells have been shown to have regulatory, innate, or pathogenic properties [1] . In murine models, DN T cells can act as regulatory T cells (Tregs) that inhibit allo-and xenograft rejection [2, 3, 4, 5] and autoimmune diabetes [6, 7] . Our previous studies showed that TCR transgenic DN T cells attenuated CD8 + T cell-induced graft-versus-host disease (GVHD) in a single class Imismatched mouse model [8] . Whether DN T cells can suppress CD4
+ T cell-mediated GVHD is not known. Human DN T cells inhibit autologous CD4
+ and CD8 + T cell proliferation in vitro [9, 10] , and the frequency of circulating DN T cells inversely correlated with the severity of GVHD in bone marrow transplantation (BMT) patients, suggesting that DN T cells might inhibit GVHD in humans [11] .
Fas or FasL mutations in mice (lpr and gld respectively) and humans (autoimmune lymphoproliferative syndrome) exhibit lymphoproliferation, autoimmunity, and DN T cell expansion. Whereas some studies implicate DN T cells in the pathogenesis of autoimmunity in these settings, lpr DN T cells can also act as Tregs in some contexts [12, 13] , for example following an infusion of allogeneic lymphocytes [12] . This feature is shared with other murine [2, 14] and human [10] DN T cells. Furthermore FasL-expressing T cells in NOD.lpr mice can resist diabetes induced by adoptively transferred T cells [15] . Whether lpr DN T cells can inhibit syngeneic CD4 + T cell responses is of interest since the latter are autoimmune effectors in lpr and gld mice [16, 17] .
IFNc, whose inflammatory role is well described, is also immunoregulatory: it helps clear activated T cells [18] , induces Foxp3 + Tregs [19] , inhibits IL-17-secreting T cells [20] , and upregulates immunoregulatory enzymes in antigen presenting cells (APCs) [21, 22] . IFNc is expressed by mouse [2, 23] , rat [24] and human [25] DN T cells but its role in DN T cell function and the underlying mechanisms are not clear.
Here, we demonstrate that alloantigen-primed BALB/c and Fas-deficient B6.lpr DN T cells can act as Tregs to inhibit GVHD mediated by syngeneic CD4
+ T cells in a semiallogeneic BMT model. Furthermore, we have identified a novel IFNc-dependent autocrine mechanism that is critical for B6.lpr DN T cell-mediated immune suppression in vitro and in vivo.
Results

DN T cells can inhibit CD4
+ T cell-mediated GVHD [26] and recipient survival were monitored daily. Mice receiving BM alone had 100% long-term survival, while mice receiving BM+CD4
+ succumbed to acute GVHD (median survival 8 days, Fig. 1A , p = 0.0003). In contrast, the CB6F1 mice treated with alloantigen-primed BALB/c cells enriched for DN T cells showed markedly reduced GVHD (5 of 7 mice survived .100 days, Fig. 1A , p = 0.0003).
Due to a very low frequency of DN T cells in normal mice, we were unable to obtain sufficient numbers of DN T cells with high purity from BALB/c mice to confirm that these results were exclusively attributable to DN T cells. On the other hand, DN T cells are greatly expanded in Fas-deficient lpr mice and can exhibit regulatory function [12, 13] , although they are generally regarded as pathogenic autoimmune effector cells within the lpr context [27, 28] . Whether they might inhibit GVHD, or in fact worsen the disease, is not known. Intriguingly, unlike allogeneic CD4 + or CD8 + T cells which cause severe GVHD [29] , infusion of purified (Fig. S1 ) B6.lpr DN T cells pre-activated by alloantigen in vivo did not cause significant illness or mortality in lethally irradiated CB6F1 mice reconstituted with B6 (H-2 b ) BM (BM+DN, Fig. 1B-C) . These mice experienced a mild, transient illness (clinical score #3, median survival .80d). To confirm that DN T cells are able to inhibit allogeneic CD4 + T cell-induced GVHD, we purified preactivated B6.lpr DN T cells and administered them to CB6F1 recipients of B6 BM and B6. Thy1.1 CD4 + T cells. Whereas recipients of BM only had no GVHD and all survived .80d (Fig. 1B) mice receiving BM+CD4 + developed acute GVHD (median survival 12d, p,0.0001). Importantly, infusion of preactivated B6.lpr DN T cells increased median survival from 12 to .80 days (log rank test; p = 0.0034), and decreased illness severity compared with BM+CD4 + treated mice (Fig. 1B-C ). These data demonstrate that infusion of allogeneic B6.lpr DN T cells does not cause severe illness and can prevent death in mice undergoing CD4
+ T cell-mediated GVHD. Furthermore, GVHD protection by B6.lpr DN T cells was associated with decreased lung, liver, and intestinal infiltration by CD4 + T cells ( Fig. 2A , left, middle, and right columns, respectively). Effector cell density in the intestine precluded accurate quantification, but we observed statistically significant reductions in alloreactive T cell numbers in the liver (p = 0.0033, Fig. 2B ) and lungs (p = 0.0151, Fig. 2C ) when B6.lpr DN T cells were included in the inoculum. Taken together, these data suggest that B6.lpr DN T cells prevent GVHD mortality by reducing CD4 + T cell infiltration of GVHD target tissues, thereby reducing organ injury.
IFNc is critical for B6.lpr DN T cell-mediated suppression of syngeneic T cell responses to alloantigen
IFNc can contribute to GVHD pathogenesis; however, early IFNc administration can inhibit GVHD [30, 31] . DN T cells from humans [9] , TCR transgenic mice [2] , rats [24] and lpr mice [23] express IFNc. To ascertain whether B6.lpr DN T cells might cause an early rise in IFNc during GVHD, serum IFNc levels were determined by ELISA 5 days after BMT. Compared with recipients of BM+CD4 + , recipients of BM+CD4 + +DN had elevated serum IFNc (Fig. 3A , p = 0.047), suggesting that IFNc might contribute to B6.lpr DN T cell-mediated suppression of GVHD.
To determine the importance of IFNc in B6.lpr DN T cell regulatory function, CFSE labelled Thy1.1
+
CD4
+ T cells were cocultured with B6.lpr DN T cells, with either neutralizing anti-IFNc mAb or isotype control IgG. IFNc neutralization slightly increased the proportion of proliferated CD4 + T cells in the absence of B6.lpr DN T cells (Fig. 3B, right histograms) . Importantly, IFNc neutralization markedly hampered the function of B6.lpr DN T cells (Fig. 3B-C) .
To confirm the importance of DN T cell-derived IFNc, we generated B6.lpr. We next assessed whether the absence of IFNc signaling in B6.lpr DN T cells might be associated with an impaired ability to suppress donor T cells in the spleen. We observed a significantly lower number of Thy1. (Fig. 6A, second and third panels and Fig. 6B ). Importantly, all 3 types of DN T cells expressed similar levels of CD69 and CD25 as a result of this stimulation (data not shown). Consistent with a role for IFNc signalling, supplementation of B6.lpr.IFNc 2/2 DN T cell cultures with IFNc partially restored surface FasL expression, although not to levels seen in IFNcsufficient B6.lpr DN T cells (Fig. 6A, fourth panel and Fig. 6B) . Similarly, neutralization of IFNc during activation of B6.lpr DN T cells reduced surface FasL expression (Fig. 6A , fifth panel and Fig. 6C ). The observed differences in FasL expression were not due to altered proteolytic processing of FasL, as the addition of the metalloproteinase inhibitor TAPI-1 during the final 18h of culture resulted in slight increases in FasL expression in all three types of DN T cells (Fig. S2) + T cells, they were unable to suppress Fas-deficient B6.lpr CD4 + T cells effectively (Fig. 7B, p,0.0001) . Furthermore, using 7AAD to identify dead cells, we observed a dose-dependent increase in cell death among proliferated B6. Thy1.1 CD4 + T cells, but not among B6.lpr CD4 + T cells (Fig. S3) . Finally, to confirm the importance of B6.lpr DN T cell FasL expression in GVHD suppression, lethally irradiated CB6F1 mice were transplanted with BM+CD4 + and either B6.lpr (FasL + ) or B6.gld (lacking functional FasL) DN T cells. In these experiments, a dose of 2.5610 6 , rather than 5610 6 , DN T cells was given to each recipient. Despite this lower dose, B6.lpr DN T cells significantly enhanced GVHD survival compared with B6.gld DN T cells ( Fig. 7C ; log rank test p = 0.0006), whereas B6.gld DN T cell-treated mice had a rate of survival comparable to mice treated with BM+CD4 + (Fig. 7C ). Collectively these data reveal that B6.lpr DN T cell regulatory function is dependent on autocrine IFNc signaling and on expression of a functional FasL molecule in vitro and during GVHD in vivo. (Fig. 4C) , and did not require APCs for this effect in vitro (Fig. 4D-E) , our findings suggested that IFNc likely acts in an autocrine fashion in B6.lpr DN T cells. Although our data do not exclude a role for B6.lpr DN T cell-derived IFNc acting on APCs in vivo, the following findings further support a role for IFNc autocrine signalling in the regulatory function of these cells in vivo: 1) B6.lpr.IFNcR 2/2 DN T cells failed to synthesize significant IFNc in vivo (Fig. 5C-D) ; 2) expression of both IFNc and its receptor by B6.lpr DN T cells was important for B6.lpr DN T cell-mediated suppression of GVHD (Fig. 5B and Fig. 5E) ; and 3) both IFNc secretion and signaling were required for B6.lpr DN T cell surface FasL expression (Fig. 6) , which was also required for GVHD inhibition (Fig. 7C) . Collectively, these data support the notion that B6.lpr DN T cells are required to release IFNc and respond to this cytokine by upregulating surface FasL upon TCR stimulation, in order to inhibit alloimmune responses by syngeneic Fassufficient CD4 + T cells. We must concede, however, that our data do not definitively demonstrate that IFNc-mediated FasL surface expression in B6.lpr DN T cells is the mechanism by which CD4 Hill and colleagues induced cardiac allograft tolerance by treating rats with autologous immature DCs and LF15-0195 [24] . Interestingly, IFNc secretion by splenic DN T cells was required for tolerance, and IFNc neutralization in vivo resulted in allograft rejection. IFNc + cells in the spleen were visualized in contact with apoptotic T cells [24] . These findings demonstrate a regulatory role for DN T cell-secreted IFNc in a different species and suggest that it is involved in the deletion of effector T cells. However, the mechanism by which IFNc was acting in that model was not determined. Our data reveal that in B6.lpr DN T cells, IFNc acts in an autocrine fashion and up-regulates surface expression of the key effector molecule FasL. Whether a similar process occurs in DN T cells from other mouse strains or species requires further investigation.
Our findings are also in keeping with recent studies on the role of IFNc in CD4 + Foxp3 + Tregs. The latter must release IFNc shortly after alloantigen encounter to prevent allograft rejection [34] . Wei and colleagues [35] showed that Foxp3 + Tregs lacking either IFNc or IFNcR could not prevent allograft rejection, accompanied by reduced STAT1 activation in these cells. Hence, a similar autocrine IFNc pathway appears to be operating in alloantigen-reactive Foxp3
+ Tregs. We have demonstrated that autocrine IFNc upregulates B6.lpr DN T cell surface expression of FasL; the latter is required for their ability to kill activated T cells and suppress GVHD (Fig. 6-7 and Fig. S3 ). Only B6.lpr DN T cells capable of secreting and responding to IFNc were able to express high levels of surface FasL (Fig. 6A) . Furthermore, inhibition of metalloproteinase activity resulted in only a slight increase in FasL expression in B6.lpr DN T cells regardless of their ability to synthesize or respond to IFNc (Fig. S2) . These data are consistent with a previous report that FasL is stored within secretory lysosomes in T cells, and subsequently externalized upon activation [36] . Our findings therefore suggest that in B6.lpr DN T cells, TCR stimulation triggers IFNc secretion, resulting in autocrine IFNc signaling and thus externalization of pre-synthesized FasL.
Interestingly, cytotoxicity of B6.lpr DN T cells toward activated CD4
+ T cells was only mildly impaired by IFNc deficiency but completely abrogated by IFNcR deficiency (Fig. 7A) . Since antigen re-encounter by previously primed effector T cells results in IFNc secretion [37] , we speculate that IFNc may be provided partially by the activated CD4 + cells in the same culture. B6.lpr.IFNcR 2/2 DN T cells, unable to respond to IFNc, would thus not be able to externalize FasL. This failure to upregulate surface FasL presumably explains their lack of cytotoxic effect.
Deletion of IFNc in MRL.lpr mice resulted in reduced autoimmunity, lymphoproliferation and mortality [38] . Indeed, IFNc has been shown to be involved in glomerulonephritis and other autoimmune phenomena in this strain [39, 40] . In contrast, lpr mice with other strain backgrounds, including C57BL/6, exhibit lymphoproliferation but only mild autoimmune manifestations in comparison with the MRL background [41, 42] . We have shown here that autocrine IFNc regulates FasL surface expression in B6.lpr DN T cells; as such, owing to the lack of Fas, deletion of IFNc or its receptor would not be predicted to influence lymphoproliferation in B6.lpr mice. Further, owing the fact that autoimmunity is already mild or absent in this strain background, an effect of IFNc deletion on this aspect of the lpr phenotype would be difficult to detect. Indeed, we observed no differences in the longevity or lymphocyte counts of age-matched B6.lpr, B6.lpr.IFNc 2/2 , and B6.lpr.IFNcR 2/2 mice (data not shown). A further important observation made in this study is that alloantigen-primed B6.lpr DN T cells caused only a very mild illness when infused into lethally irradiated allogeneic recipients (Fig. 1B-C) . In contrast, transfer of anti-CD3 and IL-23-activated B6.lpr lymphocytes into syngeneic RAG1 2/2 mice produced severe glomerulonephritis [28] , and DN T cells were shown to produce larger amounts of IL-17 than other MRL.lpr T cell subsets [28] . Moreover, DN T cells have been shown to provide help to B cells in human lupus [43] . Hence, there is strong evidence to suggest that DN T cells contribute to the pathogenesis of lupus-like disease in lpr mice. Our data therefore support the premise that the DN T cell compartment of lpr mice contains the potential for diverse immunological functions, depending on the context. Whether these diverse functions are attributable to discrete, as-yet unidentified subsets within this compartment, remains to be determined.
Taken together, our data demonstrate that alloantigen-primed DN T cells can inhibit allogeneic CD4 + T cell-induced GVHD in mice, and that IFNc plays a critical autocrine role in controlling the regulatory function of B6.lpr DN T cells. Autocrine IFNc signaling is important for sustained B6.lpr DN T cell IFNc secretion and for upregulation of surface Fas ligand expression, which in turn leads to killing of activated anti-host Fas + CD4 + T cells. The role of DN T cell-secreted IFNc in Fas-and FasLdeficient autoimmune lymphoproliferative states is unclear, and requires further investigation.
Materials and Methods
Ethics Statement
Animals were housed in the Toronto Medical Discovery Tower under specific pathogen-free conditions. The animal use protocol (#741) was approved by the University Health Network Animal Care Committee. Animal care was conducted in accordance with the policies and guidelines of the Canadian Council on Animal Care and the Province of Ontario's Animals for Research Act. 
Antibodies and flow cytometry
These mAbs were from eBioscience (San Diego, CA) or BioLegend (San Diego, CA): PE-conjugated anti-IFNc, anti-CD4, anti-CD8, anti-NK1.1, anti-CD11b, anti-CD11c, anti-CD19, anti-Gr1, Ter119, and anti-cd TCR; allophycocyaninconjugated anti-Thy1.1 and anti-CD4; FITC-conjugated antiTCRb and anti-IFNc; biotinylated anti-CD119 (IFNcR) and antiFasL; purified anti-CD28. Biotinylated antibodies were detected using PE-Cy7-conjugated streptavidin (eBioscience). Anti-CD3 antibody (clone 145-2C11) was prepared from a hybridoma in house. Anti-mouse IFNc mAb (clone H22) was from R&D Systems (Minneapolis, MN), and IgG isotype control was from eBioscience. Flow cytometry was performed on a Cytomics FC500 (Beckman Coulter, Mississauga ON), an LSR II (Becton Dickinson, Mississauga ON), or an Accuri C6 (Accuri Cytometers, Ann Arbor MI). Dead cells were excluded with propidium iodide (Sigma-Aldrich, Oakville ON), fixable viability dye eFluor450 or 7-aminoactinomycin D (7-AAD, eBioscience).
Cell purification, BMT and GVHD induction Fig. S1 ). BALB/ c DN T cells were enriched by removing B cells by adherence to IgG-coated plates followed by depletion of CD8 + and CD4 + T cells with anti-CD4 and anti-CD8 hybridoma supernatants (RL172-4 and 3.168, respectively) and Low-Tox M rabbit complement (final preparation up to 50% DN T cells with residual B cells constituting the remainder). Cell number was adjusted based DN T cell purity to ensure that a consistent number of DN T cells were used. Male CB6F1 mice aged 6-10 weeks received 13Gy c-irradiation (divided doses, .4h apart) in a Gammacell 40 137 Cs irradiator (MDS Nordion, Ottawa ON) and were infused with 2610 6 TCD BM alone or with 10 6 CD4 + T cells, with/without 2.5-5610 6 DN T cells. Survival was monitored daily. Weights and clinical scores [26] were determined 2-3 times weekly. Moribund mice (score .6 or weight loss .25%) were sacrificed. Dead mice were assigned the maximum clinical score of 10. In some experiments, mice were sacrificed 2 weeks post-BMT to obtain tissues.
Histology and immunohistochemistry
Tissue specimens were snap-frozen and stored at 280uC. Frozen sections were stained with biotinylated anti-Thy1.1 mAb (eBioscience) and horseradish peroxidase-conjugated ultrastreptavidin (ID labs, London ON). Colour was developed with NovaRed (Vector Labs, Burlington ON), with haematoxylin counterstaining. Sections were examined using a Nikon Eclipse E200 microscope (Nikon Canada Inc., Mississauga ON). A blinded observer (C.J.) counted Thy1.1 + cells in 10 random high-powered (406objective) fields. Photomicrographs were acquired using a Leica DM2000 microscope and Infinity 1 camera (Lumenera Corporation, Ottawa ON). In parallel, H&E-stained paraffin sections were examined by a pathologist (O.A.) in blinded fashion to confirm GVHD.
Suppression assay
CD4
+ T cells (10 7 cells/mL) were incubated (10 minutes, 37uC) in PBS containing 1 mM CFSE (Invitrogen, Carlsbad CA), followed by quenching with FBS (Gibco, Carlsbad CA). Cells were washed in a-minimum essential medium with 10% FBS, 50 mM b-mercaptoethanol, 0.1mg/mL penicillin and 0.1 mg/mL streptomycin (CM). 10 5 CFSE labelled cells were cultured for 5 days with 2610 5 irradiated (20Gy) CB6F1 splenocytes and 50 U/mL recombinant human IL-2 (Proleukin, Chiron Corporation, Emeryville CA). Some experiments were performed using plate bound anti-CD3 and soluble anti-CD28 (5 mg/mL) antibodies instead of irradiated CB6F1 splenocytes. Purified DN T cells were added in varying ratios. Propidium iodide-negative responder cells were identified with anti-CD4 and/or anti-Thy1.1 antibodies and CFSE and subjected to flow cytometry. Percent suppression was calculated using the formula:
In some experiments, anti-IFNc mAb (2.5 mg/ mL) or isotype control were added. In others, 7-AAD staining and CFSE dilution were jointly examined. Cell death in the presence of B6.lpr DN T cells was compared to cell death in their absence by calculating fold change, defined as (%7-AAD + (DN+CD4 + ))/ (%7-AAD + (CD4 + only)).
IFNc staining
Two million splenocytes were cultured for 4 h in 2 mL CM containing GolgiStop (monensin, 1.5 mL/mL, BD Biosciences, Mississauga ON), with/without 50 ng/mL PMA and 500 ng/mL ionomycin (Sigma-Aldrich). Cells were stained for TCRb, CD4, CD8, and NK1.1. IFNc staining was performed with an intracellular staining kit (eBioscience).
Cytotoxicity assay
The JAM assay [44] was used to quantitate cytotoxicity as described previously [12] . Briefly, 2610 6 B6 CD4 + T cells were added to 10610 6 irradiated CB6F1 splenocytes and 50 U/mL IL-2 in 2 mL CM. After 4 days, 10 mCi/mL 
DN T cell FasL expression
Five million spleen and lymph node cells from B6.lpr, B6.lpr.IFNc 2/2 , and B6.lpr.IFNcR 2/2 mice were cultured in 2 mL CM in plates coated with anti-CD3 mAb, along with 50 U/ mL IL-2 and 5 mg/mL soluble anti-CD28 mAb with/without 100 ng/mL recombinant mouse IFNc (R&D Systems). In some cases anti-IFNc antibody (2.5 mg/mL) or isotype control were included; in others, 50 mM TAPI-1 [45] (Peptides International, Louisville KY) or DMSO vehicle were added for the final 18h of culture. After 48 h, cells were stained for TCRb, CD4, CD8, and NK1.1. Half of the cells were stained for surface FasL expression and fixed; the remainder were stained intracellularly for FasL.
Data Analysis
Flow cytometry data were analyzed and presented with FlowJo 7 (Treestar, Ashland OR). Graphical presentation and statistical analysis of data were performed with Prism 5.0 (GraphPad, La Jolla CA). Survival analysis was performed using the log-rank test. Variance between two groups was assessed with either Student's t test (in some cases with Welch's correction for unequal variances) or the Mann-Whitney test; three or more groups were analyzed by ANOVA, in some cases with Bonferroni's post-test to compare groups, or the Kruskal-Wallis test in the case of non-parametric data. A p value of less than 0.05 was considered statistically significant. Error bars in all graphs represent standard deviations. Figure S1 Purification of B6.lpr DN T cells. Pooled spleen and lymph node cells from B6.lpr mice were incubated with PEconjugated antibodies to CD4, CD8, NK1.1, CD11b, CD11c, Ter119, cdTCR, and CD19, washed, and incubated with anti-PE microbeads. PE + cells were then removed using LD columns. Aliquots of the pre-column population (left panels) and the negative fraction (right panels) were stained with FITC-conjugated 
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